PP
ANIK icon

Paloma Partners’s Anika Therapeutics ANIK Stock Holding History

Paloma Partners’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7,465
Closed -$387K – 1223
2019
Q4 		$387K Buy
+7,465
New +$434K 0.01% 1579
2019
Q1 		– Sell
-8,200
Closed -$276K – 1671
2018
Q4 		$276K Buy
+8,200
New +$296K 0.01% 891
2017
Q1 		– Sell
-8,929
Closed -$437K – 1945
2016
Q4 		$437K Buy
+8,929
New +$413K ﹤0.01% 1574
2016
Q3 		– Sell
-4,342
Closed -$233K – 1818
2016
Q2 		$233K Buy
+4,342
New +$205K ﹤0.01% 1884
2015
Q4 		– Sell
-15,600
Closed -$497K – 1684
2015
Q3 		$497K Buy
+15,600
New +$544K 0.01% 1032

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Paloma Partners's ANIK Position: Q1 2020 in Review

Paloma Partners sold out of Anika Therapeutics (ANIK) in Q1 2020, closing a stake of 7,465 shares — an estimated $387K sold.

Paloma Partners first reported a position in ANIK in Q3 2015 and held it in 5 quarters. The position peaked at $497K in Q3 2015. 163 funds tracked by Wall St. Rank hold ANIK as of Q1 2020.

  • Paloma Partners reported no remaining Anika Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Paloma Partners sold 7,465 Anika Therapeutics shares in Q1 2020, an estimated $387K.
  • Paloma Partners first reported a position in Anika Therapeutics in Q3 2015 and held it in 5 quarters.
  • Paloma Partners's Anika Therapeutics position peaked at $497K in Q3 2015.
  • 163 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.